Tissue insulin sensitivity and body weight in polycystic ovary syndrome

Clinical Endocrinology

Volumn 55, Issue 2, 2001, Pages 191-199

  Marsden, Philippa J ^a   Murdoch, Alison P ^b   Taylor, Roy ^c  

^a UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

^b INSTITUTE OF HUMAN GENETICS   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLGLUCOSE; ANDROSTENEDIONE; INSULIN; INSULIN RECEPTOR; LUTEINIZING HORMONE; TESTOSTERONE;

ADIPOCYTE; ADULT; AMENORRHEA; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE TRANSPORT; HIRSUTISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MEASUREMENT; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; STIMULATION; TESTOSTERONE BLOOD LEVEL;

ADIPOCYTES; ADULT; BODY WEIGHT; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GONADOTROPINS; HUMANS; INSULIN RESISTANCE; LINEAR MODELS; LUTEINIZING HORMONE; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; RECEPTOR, INSULIN;

EID: 0034825343     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01303.x     Document Type: Article

References (54)

1. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism
2. Changing pituitary reactivity to follicle stimulating hormone and luteinising hormone releasing hormone after induced ovulatory cycles and after anovulation in patients with polycystic ovarian disease
3. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
4. Impact of obesity on insulin action in volunteers with normal glucose tolerance: Demonstration of a threshold for the adverse effect of obesity
5. Insulin resistance in non-obese patients with polycystic ovarian disease
6. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
7. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus
8. Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients
9. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome
10. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
11. Characterisation of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinaemia
12. The impact of obesity and chronic hyperinsulinaemia on gonadotrophin release and gonadal steroid secretion in the polycystic ovary syndrome
13. Profound peripheral insulin resistance independent of obesity, in polycystic ovary syndrome
14. The insulin sensitising agent troglitazone: A novel therapy for the polycystic ovary syndrome
15. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
16. Clinical assessment of body hair growth in women
17. Polycystic ovarian disease: Diagnostic methods
18. Polycystic ovary syndrome: A changing perspective
19. The polycystic ovary. 1. Clinical and histological features
20. Glucagon in women with polycystic ovary syndrome (PCO): Relationship to abnormalities of insulin and androgens
21. Weight loss is associated with correction of gonadotrophin and sex steroid abnormalities in the obese anovulatory female
22. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance- related polycystic ovary syndrome
23. The syndromes of insulin resistance and acanthosis nigricans - Insulin receptor disorders in man
24. Hyperandrogenism, insulin resistance, acanthosis nigricans and SLE associated with insulin receptor antibodies
25. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: An analysis of 263 consecutive cases
26. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
27. The effect of weight loss on sex steroid secretion and binding in massively obese women
28. Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease
29. Severe impairment of insulin action in adipocytes from amenorrhoeic subjects with polycystic ovary syndrome
30. Adipocyte insulin action during the normal menstrual cycle
31. Adipocyte insulin action following ovulation in polycystic ovarian syndrome
32. Adipocyte insulin action in hypogonadotrophic hypogonadism
33. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomised, double-blind placebo-controlled 6-month trial, followed by open, long term clinical evaluation
34. Insulin, somatotrophic, and luteinising hormone axes in lean and obese women with polycystic ovarian syndrome: Common and distinct features
35. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
36. LH in polycystic ovary syndrome: Reproducibility and pulsatile secretion
37. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
38. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
39. Effects of obesity on gonadotrophin secretion in patients with polycystic ovarian disease
40. Insulin resistance in patients with polycystic ovaries: Its relationship to body weight and androgen levels
41. Clinical and hormonal characteristics of obese amenorrhoeic hyperandrogenic women before and after weight loss
42. Insulin receptor binding and receptor-mediated insulin degradation in human adipocytes
43. Hexose transport in human adipocytes: Factors influencing the response to insulin and kinetics of methylglucose and glucose transport
44. The role of adrenal hyperandrogenism, insulin resistance and obesity in the pathogenesis of polycystic ovarian syndrome
45. Amenorrhoea associated with bilateral polycystic ovaries
46. Medical implications of ultrasonically detected polycystic ovaries
47. Coronary heart disease risk factors in women with polycystic ovary syndrome
48. Insulin secretion, adipocyte insulin binding and insulin sensitivity in thyrotoxicosis
49. Insulin sensitivity and fertility
50. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, hyperandrogenaemia and systolic blood pressure, while facilitating normal menses and pregnancy
51. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
52. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome
53. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome
54. Review article: The polycystic ovary syndrome